기초과학융합연구소

•제목: β-cell engineering by CRISPR-Cas9 toward cell-based therapeutics for diabetes

•초록:

Cell-based therapy for type 1 diabetes using stem cell-derived β cells is still in its early stages due to several problems such as immune rejection and inadequate response to glucose. To overcome these barriers, we aim to engineer β-cell therapeutics by CRISPR-Cas9 to endow them with new functions such as immunomodulatory functions. Toward this goal, a genome-editing platform was first developed that enables efficient gene fragment knock-in at diverse genomic loci and in multiple cell types. Next, the platform was successfully applied for creating designer β-cells that secrete functional proteins and peptides. Recent works on genome editing and β-cell engineering will be discussed in the presentation.

——런치 세미나 결과 안내——-

총 36명 참여, 임동현 교수님께서 유익한 발표 진행해주셨습니다.